---
title: Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients
nct_id: NCT00982995
overall_status: TERMINATED
phase: PHASE2
sponsor: University of Michigan Rogel Cancer Center
study_type: INTERVENTIONAL
primary_condition: Nausea
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00982995.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00982995"
ct_last_update_post_date: 2015-12-04
last_seen_at: "2026-05-12T07:13:17.114Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients

**Official Title:** UMCC 2008.048 Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients

**NCT ID:** [NCT00982995](https://clinicaltrials.gov/study/NCT00982995)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** site terminated due to lack of enrollment
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 3
- **Lead Sponsor:** University of Michigan Rogel Cancer Center
- **Conditions:** Nausea, Vomiting, Terminally Ill
- **Start Date:** 2010-11
- **Completion Date:** 2013-05
- **CT.gov Last Update:** 2015-12-04

## Brief Summary

The primary objective of this study is to determine the complete response (no vomiting and no need for other medications to treat nausea) in terminally ill patients suffering from nausea and/or vomiting, who are treated with palonosetron. Another objective is to determine the partial response (relief of nausea and vomiting to the extent that the patient wishes to continue treatment with palonosetron) after being treated with palonosetron. Palonosetron is currently approved by the FDA to prevent nausea and vomiting associated with chemotherapy. The investigators are testing this medication to see if it can help to relieve nausea and vomiting not associated with chemotherapy.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Patient must be at least 18 years old.
2. Patient must have a terminal diagnosis, with estimated survival of 6 months or less.
3. Patients must have nausea and/or vomiting, not relieved with 1 or more anti-nausea medications. If the patient is treated with an anti-nausea medication, a minimum of 2 hours should pass to ensure that the medication is given a chance to be effective. If there is no relief after 2 hours, then the patient may be treated with palonosetron.
4. Patient's medications must be reviewed. Any medications possibly causing nausea should be stopped if possible. For example, if an opiate is suspected of causing nausea, another opiate should be substituted. However, if this is not effective, or if a medication change cannot be made, then the patient would be eligible for this study.
5. Patient must be able to understand and sign informed consent
6. Patients who have a bowel obstruction that will not be relieved by surgery may be enrolled. This includes patients whose obstruction is technically unresectable, or who are medically too ill to endure a surgery, or who refuse surgical intervention for any reason

Exclusion Criteria:

1. Patient has received chemotherapy in the past 28 days.
2. Assessment of possible causes of the nausea and vomiting should be done and recorded. If a reversible cause of the nausea is identified, that cause should be treated if possible. If the treatment relieves the nausea, then the patient is excluded from this study. Possible reversible causes of nausea and vomiting that should be excluded are:

   * Other medical conditions such as benign positional vertigo, etc.
```

## Arms

- **Palonosetron** (EXPERIMENTAL) — Palonosetron 0.25 mg I.V. bolus

## Interventions

- **Palonosetron** (DRUG) — Palonosetron 0.25 mg as an I.V. bolus. After Palonosetron treatment, no other nausea medication will be given for 2 hours. At that point, if no relief from nausea or vomiting has occured then other anti-nausea medications may be prescribed, and patient will be taken off study. If relief from nausea and vomiting as a result of the Palonosetron occurs, patient will not receive any more anti-nausea medication unless nausea recurs. If it does recur and patient wishes to be retreated with Palonosetron. This may be repeated for a total of 3 doses, as long as it is providing relief.

## Primary Outcomes

- **To Determine the Complete Response (no Vomiting and no Need for Nausea Rescue Medication) in Terminally Ill Patients Suffering From Nausea and/or Vomiting, Treated With Palonosetron.** _(time frame: 96 hours after dosing)_

## Secondary Outcomes

- **To Determine the Partial Response (Relief of Nausea and Vomiting to the Extent That the Patient Desires Continued Dosing With Palonosetron,) in Terminally Ill Patients Suffering From Nausea and/or Vomiting, Treated With Palonosetron** _(time frame: 96 hours after dosing)_

## Locations (1)

- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university of michigan comprehensive cancer center|ann arbor|michigan|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00982995.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00982995*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*